Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page
- Check7 days agoChange DetectedThe clinical trial record for a Phase 3 study of daclatasvir and asunaprevir in treatment-naive patients with hepatitis C is now available, with study design, participant criteria, locations, and outcome measures. The record indicates the study is completed and is no longer recruiting.SummaryDifference54%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces an NIH website transition and says some content may use “Super Intelligence” instead of “Artificial Intelligence.” The page content below remains a 403 error.SummaryDifference1%

- Check27 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, indicating an access restriction or server issue. The visible screen displays the standard 403 notice and site chrome rather than the ClinicalTrials.gov study details.SummaryDifference17%

Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.